pembrolizumab,nivolumab
merck,bms
['kn716', 'cm76k ', 'lung', 'pembro', 'nivo']
 as expected. hazard ratio difference was driven by the placebo arm doing much worse in cm76k than kn716. anti-pd1 arm almost exactly the same at 12 month landmark rfs - c/w w all studies of nivo vs pembro in all dz's except for one lung cancer trial...
Immunotherapy of Cancer • Melanoma • Phase I Clinical Trials • Targeted Therapies for Cancer • Lab: @ImmunoTiil • Disclosures at https://t.co/mcWOaTaiZn…